## titioner's Docket No. MPI00-252P1RM

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In resplication of:

Curtis, Rory A.J.

Mcation No.:

09/875,321

Group No.:

1646

Filed:

June 6, 2001

Examiner:

PAK, Michael D.

For:

52906, 33408, AND 12189, NOVEL POTASSIUM CHANNEL FAMILY

MEMBERS AND USES THEREOF

Confirmation No.: 7512

Mail Stop Issue Fee **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

### LETTER ACCOMPANYING AMENDMENT AFTER ALLOWANCE (37 C.F.R. Section 1.312)

1. l	1. Please make the amendments shown in the attached papers in this application in the					
	<ul><li>( ) abstract.</li><li>(X) specification.</li><li>( ) drawings.</li><li>( ) claims.</li></ul>	•				
2.	Type of amendment:					
	(X) Correction of formal matters As shown in the remarks of	s the attached paper, these (1) are needed for proper disclosure or				
	CERTIFICATION UN	DER 37 C.F.R. SECTIONS 1.8(a) and 1.10*				
I he	reby certify that, on the date shown below, this co	rrespondence is being:				
		MAILING				
X	deposited with the United States Postal Ser Patents, P.O. Box 1450, Alexandria, VA 2:	vice in an envelope addressed to the Mail Stop Issue Fee, Commissioner for				
	37 C.F.R. SECTION 1.8(a)	37 C.F.R. SECTION 1.10*				
	with sufficient postage as first class mail.	as "Express Mail Post Office to Addressee"  Mailing Label No. <u>EV512402362US</u>				
		TRANSMISSION				
	transmitted by facsimile to the Patent and T	rademark Office.				
		Signature				
Date	e: July 9, 2004	Sean Hunziker (type or print name of person certifying)				
Dan		(type or print name of person certifying)				

<sup>\*</sup>WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

# Practitioner's Docket No. MPI00-252P1RM

		protection of the invention and (2) require no substantial amount of additional work on the part of the PTO.			
	()	Other (affects the disclosure, the scope of any claim or adds a claim) (M.P.E.P. Section 714.16, 7th ed.)			
		As shown in the remarks in the attached supplemental page(s), there is stated the reason (1) why the amendment is needed, (2) why the proposed amended or new claims require no additional search or examination, (3) why the claims are patentable, and (4) why they were not earlier presented.			
3.	The is	sue fee:			
	( ) (x) ( )	has not been paid. is paid separately herewith. was paid on			
4.	Reque	est for Entry of Amendments:			
(a)	(X)	Because the issue fee has been paid or is paid herewith, the applicant hereby requests entry of the attached amendments. (37 C.F.R. Section 1.312).			
5.	Fees:				
	(x)	Please charge Account 501668 for any fees that may be required by the filing of this paper.			
July 9	2004	MILLENNIUM PHARMACEUTICALS, INC.			
		By Conference			
		Kerri Pollard Schray			
		Registration No. 47,066			
		40 Landsdowne Street Cambridge, MA 02139			
		Telephone - 617-551-3676			
		Facsimile - 617-551-8820			

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Curtis, Rory A.J.

Application No.:

09/875,321

Group No.:

1646

Filed:

June 6, 2001

Examiner:

PAK, Michael D.

For:

52906, 33408, AND 12189, NOVEL POTASSIUM CHANNEL FAMILY MEMBERS

AND USES THEREOF

Mail Stop Issue Fee **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450 **Confirmation No. 7512** 

#### **TRANSMITTAL**

- 1. Transmitted herewith for this application is/are:
  - This Transmittal (2 pages in duplicate);
  - Letter Accompanying Amendment After Allowance (2 pages); b.
  - Amendment After Allowance (3 pages); c.
  - Transmittal of Payment of Issue Fee (1 page in duplicate); d.
  - Part B Fees Transmittal (1 page in duplicate); and e.
  - f. Return Postcard.

#### **STATUS**

2. Applicant is other than a small entity.

	02				
I hereby	certify that, on the date shown below, this correspond	ence is being:			
	MA	AILING			
×	deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.				
	37 C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*		
	with sufficient postage as first class mail.	E	as "Express Mail Post Office to Addressee" Mailing Label No. EV512402362US		
	TRAN	SMISSION			
	transmitted by facsimile to the Patent and Trademark	Office.	en At		
Date:	July 9, 2004	Signat	ture d		
			lunziker		
		(type o	or print name of person certifying)		

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

\*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

## Practitioner's Docket No. MPI00-252P1RM

### FEE DEFICIENCY

3. If any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.

J	ulv	9.	2004	

MILLENNIUM PHARMACEUTICALS, INC.

Bv

Kerri Pollard Schray Reg. No. 47,066 40 Landsdowne Street Cambridge, MA 02139 Telephone – (617) 551-3676 Facsimile – (617) 551-8820